Disclosed is a stable oral pharmaceutical composition for treating or preventing esophageal inflammation or symptoms associated therewith comprising: a) a therapeutically effective amount of a topically active corticosteroid, the topically active corticosteroid being budesonide, fluticasone, mometasone furoate, ciclesonide, triamcinolone, beclomethasone, or a pharmaceutically acceptable ester or salt thereof, or a combination thereof, b) an antioxidant, c) a buffer, d) a surfactant, e) a preservative, a flavoring agent, a sweetener, or a combination thereof, f) at least one additional excipient that increases the interaction of the composition with a surface of the esophagus, g) dextrose in an amount of 0-500 mg per mL of the composition, and h) a liquid vehicle, wherein the composition is chemically and physically stable, wherein the composition remains substantially uniform for at least 1 day, and wherein the composition is suitable for single or multiple dose administration.
